ARS Pharmaceuticals, Inc. Share-based Payment Arrangement, Amount Capitalized
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Payment Arrangement, Amount Capitalized of $400.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2026-06-30 was $400.00K, a 33.33% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2026-03-31 was $400.00K, a 100.00% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2025-12-31 was $300.00K, a 50.00% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for the quarter ending 2025-09-30 was $300.00K, a 200.00% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for fiscal 2025 was $1.10M, a 266.67% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for fiscal 2024 was $300.00K.
- ARS Pharmaceuticals, Inc. share-based payment arrangement, amount capitalized for fiscal 2023 was $0.00.
| Period end | Share-based Payment Arrangement, Amount Capitalized 3 month | Share-based Payment Arrangement, Amount Capitalized 6 month | Share-based Payment Arrangement, Amount Capitalized 9 month | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|---|---|---|
| 2026-06-30 | $400.00K 10-Q · filed 2026-08-13 | $800.00K 10-Q · filed 2026-08-13 | $1.10M derived: sum of 3 quarters · filed 2026-08-13 | $1.40M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $400.00K 10-Q · filed 2026-05-15 | $700.00K derived: sum of 2 quarters · filed 2026-05-15 | $1.00M derived: sum of 3 quarters · filed 2026-05-15 | $1.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $600.00K derived: sum of 2 quarters · filed 2026-03-09 | $900.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.10M 10-K · filed 2026-03-09 |
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-10 | $600.00K derived: sum of 2 quarters · filed 2026-08-13 | $800.00K 10-Q · filed 2025-11-10 | $1.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $300.00K 10-Q · filed 2026-08-13 | $500.00K 10-Q · filed 2026-08-13 | $700.00K derived: sum of 3 quarters · filed 2026-08-13 | $800.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-15 | $400.00K derived: sum of 2 quarters · filed 2026-05-15 | $500.00K derived: sum of 3 quarters · filed 2026-05-15 | $500.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $300.00K derived: sum of 2 quarters · filed 2026-03-09 | $300.00K derived: sum of 3 quarters · filed 2026-03-09 | $300.00K 10-K · filed 2026-03-09 |
| 2024-09-30 | $100.00K 10-Q · filed 2025-11-10 | $100.00K derived: sum of 2 quarters · filed 2025-11-10 | $100.00K 10-Q · filed 2025-11-10 | $100.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2025-08-13 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 10-K · filed 2025-03-20 | ||
| 2023-09-30 | $0.00 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |